활동혈압측정(ABPM) 기기 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

The global ambulatory blood pressure monitoring devices market size was valued at USD 1.6 billion in 2025 and is projected to grow from USD 1.7 billion in 2026 to USD 3.8 billion by 2033, at a CAGR of 11.6% from 2026 to 2033. North America dominated the global market, accounting for the largest revenue share of 40.0% in 2025. The market is primarily driven by the growing geriatric population, increasing prevalence of chronic diseases such as hypertension, and ongoing technological advancements in blood pressure monitoring solutions. According to the World Health Organization (WHO) Hypertension Fact Sheet updated in 2025, an estimated 1.4 billion adults aged 30-79 years worldwide were living with hypertension in 2024. Hypertension remains one of the leading causes of premature mortality globally and contributes significantly to the burden of cardiovascular diseases, including heart attack, stroke, and kidney disorders.

Furthermore, WHO reports that nearly two-thirds of individuals with hypertension reside in low- and middle-income countries, where diagnosis and disease management remain major healthcare challenges. These factors are increasing the need for reliable blood pressure screening and continuous monitoring solutions, thereby driving demand for ambulatory blood pressure monitoring devices worldwide.

The growing geriatric population is a key factor driving demand for ambulatory blood pressure monitoring (ABPM) devices. According to the United Nations International Day of Older Persons update published in 2025, the global population aged 60 years and above reached approximately 1.2 billion in 2025 and is projected to increase to 2.1 billion by 2050. As older adults are more susceptible to hypertension, cardiovascular diseases, and other age-related health conditions, the expanding elderly population is expected to drive sustained demand for continuous, accurate, and non-invasive blood pressure monitoring technologies.

Furthermore, ongoing technological advancements in ABPM devices are expected to support market growth throughout the forecast period. The increasing adoption of digital, connected, and mobile-enabled blood pressure monitoring technologies is enhancing patient convenience, data accessibility, and remote care capabilities. For instance, in April 2026, OMRON Healthcare announced its support for May Measurement Month 2026 through the donation of 3,000 advanced blood pressure monitors capable of detecting probable atrial fibrillation, highlighting the industry's growing focus on early disease detection and remote cardiovascular monitoring. Such developments are expected to accelerate the adoption of advanced blood pressure monitoring solutions and strengthen the broader market for ambulatory monitoring technologies worldwide.

Global Ambulatory Blood Pressure Monitoring Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ambulatory blood pressure monitoring devices market report based on product, end use, and region:

• Product Outlook (Revenue, USD B illion, 2021 - 2033)

Ambulatory Blood Pressure Monitors

Instrument & Accessories

• Blood Pressure Cuffs
• Others Type
• End Use Outlook (Revenue, USD B illion, 2021 - 2033)

Hospitals

Ambulatory Surgical Centers & Clinics

Homecare

• Regional Outlook (Revenue, USD B illion , 2021 - 2033)

North America

• U.S.
• Canada
• Mexico

Europe

• UK
• Germany
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway

Asia Pacific

• Japan
• China
• India
• South Korea
• Australia
• Thailand

Latin America

• Brazil
• Argentina

Middle East and Africa (MEA)

• South Africa
• Saudi Arabia
• UAE
• Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. End-use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in Asia Pacific
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. End-use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Ambulatory Blood Pressure Monitoring Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Increasing prevalence of chronic diseases
• 3.3. Ambulatory Blood Pressure Monitoring Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Ambulatory Blood Pressure Monitoring Devices Market: Prevalence Data, By Region
  • 3.4.1. North America
    • 3.4.1.1. U.S.
    • 3.4.1.2. Canada
    • 3.4.1.3. Mexico
  • 3.4.2. Europe
    • 3.4.2.1. UK
    • 3.4.2.2. Germany
    • 3.4.2.3. France
    • 3.4.2.4. Italy
    • 3.4.2.5. Spain
    • 3.4.2.6. Denmark
    • 3.4.2.7. Sweden
    • 3.4.2.8. Norway
  • 3.4.3. Asia Pacific
    • 3.4.3.1. Japan
    • 3.4.3.2. China
    • 3.4.3.3. India
    • 3.4.3.4. South Korea
    • 3.4.3.5. Australia
    • 3.4.3.6. Thailand
  • 3.4.4. Latin America
    • 3.4.4.1. Brazil
    • 3.4.4.2. Argentina
  • 3.4.5. Middle East and Africa (MEA)
    • 3.4.5.1. South Africa
    • 3.4.5.2. Saudi Arabia
    • 3.4.5.3. UAE
    • 3.4.5.4. Kuwait

Chapter 4. Ambulatory Blood Pressure Monitoring Devices Market: Product Estimates & Trend Analysis

• 4.1. Product Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global ambulatory blood pressure monitoring devices Market by Product Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Ambulatory blood pressure monitors
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Instrument & accessories
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.2. Blood Pressure Cuffs
    • 4.6.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.6.3. Others
    • 4.6.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Ambulatory Blood Pressure Monitoring Devices Market: End-use Estimates & Trend Analysis

• 5.1. End-use Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global ambulatory blood pressure monitoring devices Market by End-use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. Hospitals
    • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
  • 5.4.2. Ambulatory Surgical Centers & Clinics
    • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Homecare
    • 5.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Ambulatory Blood Pressure Monitoring Devices Market: Regional Estimates & Trend Analysis by Product & End-use

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million) (Number of Patients Treated in Thousands)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2023
  • 7.3.4. Omron Healthcare Welch Allyn, Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. A&D Medical Inc.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Microlife Corporation
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Daray Medical
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Withings
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Briggs Healthcare
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. GE Healthcare
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Rossmax International Ltd.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. GF Health Products Inc
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Spacelabs Healthcare Inc.
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Philips Healthcare
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives
  • 7.3.15. Biobeat
    • 7.3.15.1. Company overview
    • 7.3.15.2. Financial performance
    • 7.3.15.3. Product benchmarking
    • 7.3.15.4. Strategic initiatives
  • 7.3.16. Spacelabs Healthcare Inc
    • 7.3.16.1. Company overview
    • 7.3.16.2. Financial performance
    • 7.3.16.3. Product benchmarking
    • 7.3.16.4. Strategic initiatives
  • 7.3.17. Bosch & Sohn GmbH & Co. KG
    • 7.3.17.1. Company overview
    • 7.3.17.2. Financial performance
    • 7.3.17.3. Product benchmarking
    • 7.3.17.4. Strategic initiatives
  • 7.3.18. GE Company,
    • 7.3.18.1. Company overview
    • 7.3.18.2. Financial performance
    • 7.3.18.3. Product benchmarking
    • 7.3.18.4. Strategic initiatives
  • 7.3.19. Schiller AG
    • 7.3.19.1. Company overview
    • 7.3.19.2. Financial performance
    • 7.3.19.3. Product benchmarking
    • 7.3.19.4. Strategic initiatives
  • 7.3.20. DAIFUKU CO. LTD
    • 7.3.20.1. Company overview
    • 7.3.20.2. Financial performance
    • 7.3.20.3. Product benchmarking
    • 7.3.20.4. Strategic initiative